Next generation targeted protein therapeutics
Latest News
02/11/2011 ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine
01/05/2011 ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
11/23/2010 ImmunGene Receives $244,479 Grant Under The Patient Protection And Affordable Care Program For Its Anti-Cancer Technology
11/11/2010 ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
02/11/2011 ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine
01/05/2011 ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
11/23/2010 ImmunGene Receives $244,479 Grant Under The Patient Protection And Affordable Care Program For Its Anti-Cancer Technology
11/11/2010 ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
Welcome to
ImmunGene
ImmunGene is a privately held drug discovery and development company, developing next generation of monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders and other diseases.
ImmunGene is a privately held drug discovery and development company, developing next generation of monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders and other diseases.
Our focus
ImmunGene is working to make our novel drug candidates for treating diseases that affect tens of millions of people worldwide. ImmunGene's primary focus is on safe and effective treatments for cancer.
ImmunGene also has programs underway to treat other potentially devastating diseases, including infections.
ImmunGene is working to make our novel drug candidates for treating diseases that affect tens of millions of people worldwide. ImmunGene's primary focus is on safe and effective treatments for cancer.
ImmunGene also has programs underway to treat other potentially devastating diseases, including infections.
Our approach
ImmunGene is leveraging promising science to tap the power of the immune systems to develop therapeutic antibodies that are highly optimized for efficacy and a superior safety profile.
Our technology allows us to fuse cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines.
ImmunGene is leveraging promising science to tap the power of the immune systems to develop therapeutic antibodies that are highly optimized for efficacy and a superior safety profile.
Our technology allows us to fuse cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines.